Gilead Sciences Inc.'s $11.9bn acquisition of chimeric antigen receptor T cell (CAR-T) therapy developer Kite Pharma Inc. will make cell therapy the foundation of the company's oncology platform as it diversifies its revenue base beyond small molecule antiviral medicines.
Gilead executives said in a same-day call about the transaction announced on Aug. 28 that the company will build its oncology business around cell therapies with an eye on improving Kite's products and developing combination regimens that incorporate CAR-T and T-cell receptor (TCR) therapies
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?